The content on this site is intended for healthcare professionals only
Prof Harris speaks at the Highlighting Welsh Cancer Research Conference about the use of blood-based tumour markers, as reviewed by the Early Cancer Detection Consortium.
Highlighting circulating tumour cells (CTCs) and DNA methylation as assays currently available, he considers the shortfalls in specificity and clinical adoption of biomarkers, and introduces Grail as an upcoming assay aiming for better outcomes.
Prof Harris also discusses Raman spectroscopy, by which plasma may be assessed through laser scattering to determine the presence of CTCs.
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Cancer mutation prediction using artificial intelligence
Best practice in HRRm testing in patients with metastatic prostate cancer
SABCS 2023: Latest breast cancer diagnostics guidelines
Choosing Wisely in radiology Tanzania
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
Why tumour markers are not recommended as screening tests
Choosing Wisely to mitigate financial toxicity in cancer care in Africa
Moving to the future: Artificial intelligence in surgery
